Show simple item record

dc.contributor.authorDowling, RJOen_US
dc.contributor.authorSparano, JAen_US
dc.contributor.authorGoodwin, PJen_US
dc.contributor.authorBidard, F-Cen_US
dc.contributor.authorCescon, DWen_US
dc.contributor.authorChandarlapaty, Sen_US
dc.contributor.authorDeasy, JOen_US
dc.contributor.authorDowsett, Men_US
dc.contributor.authorGray, RJen_US
dc.contributor.authorHenry, NLen_US
dc.contributor.authorMeric-Bernstam, Fen_US
dc.contributor.authorPerlmutter, Jen_US
dc.contributor.authorSledge, GWen_US
dc.contributor.authorThorat, MAen_US
dc.contributor.authorBratman, SVen_US
dc.contributor.authorCarey, LAen_US
dc.contributor.authorChang, MCen_US
dc.contributor.authorDeMichele, Aen_US
dc.contributor.authorEnnis, Men_US
dc.contributor.authorJerzak, KJen_US
dc.contributor.authorKorde, LAen_US
dc.contributor.authorLohmann, AEen_US
dc.contributor.authorMamounas, EPen_US
dc.contributor.authorParulekar, WRen_US
dc.contributor.authorRegan, MMen_US
dc.contributor.authorSchramek, Den_US
dc.contributor.authorStambolic, Ven_US
dc.contributor.authorWhelan, TJen_US
dc.contributor.authorWolff, ACen_US
dc.contributor.authorWoodgett, JRen_US
dc.contributor.authorKalinsky, Ken_US
dc.contributor.authorHayes, DFen_US
dc.date.accessioned2020-01-06T11:52:49Z
dc.date.issued2019-12en_US
dc.identifier.citationJNCI cancer spectrum, 2019, 3 (4), pp. pkz049 - ?en_US
dc.identifier.issn2515-5091en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3482
dc.identifier.eissn2515-5091en_US
dc.identifier.doi10.1093/jncics/pkz049en_US
dc.description.abstractLate disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened in Toronto, Canada, in February 2018 to review the current understanding of late recurrence and to identify critical issues that require future study. The underlying biological causes of late recurrence are complex, with the processes governing cancer cell dormancy, including immunosurveillance, cell proliferation, angiogenesis, and cellular stemness, being integral to disease progression. These critical processes are described herein as well as their role in influencing risk of recurrence. Moreover, observational and interventional clinical trials are proposed, with a focus on methods to identify patients at risk of recurrence and possible strategies to combat this in patients with estrogen receptor-positive BC. Because the problem of late BC recurrence of great importance, recent advances in disease detection and patient monitoring should be incorporated into novel clinical trials to evaluate approaches to enhance patient management. Indeed, future research on these issues is planned and will offer new options for effective late recurrence treatment and prevention strategies.en_US
dc.formatElectronic-eCollectionen_US
dc.format.extentpkz049 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleToronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-07-08en_US
rioxxterms.versionofrecord10.1093/jncics/pkz049en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
rioxxterms.licenseref.startdate2019-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJNCI cancer spectrumen_US
pubs.issue4en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublisheden_US
pubs.volume3en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/